Long-acting lanreotide 120 mg every 4 weeks reduces liver volume in patients with polycystic liver diseases.
Animal studies that demonstrated that the inhibition of hepatic and renal cystogenesis is dose dependent.
Dr Temmerman and colleagues from Belgium investigated the safety and efficacy of two different LAN doses in polycystic liver diseases patients.
The 6-month results of the LOCKCYST I trial, its extension study, and the LOCKCYST II trial were pooled.
Long-acting lanreotide at baseline and month 6 was measured by CT-scan and blindly re-analyzed by 2 independent radiologists.
|Severe side effects with long-acting lanreotide 120 mg was 16%|
|Alimentary Pharmacology & Therapeutics|
The study population consisted of 3 groups.
Each received treatment every 4 weeks during 6 months plus placebo, or long-acting lanreotide at 90 mg or 120 mg.
The team reported excellent inter-observer variability and agreement in the calculation of Long-acting lanreotide.
The researchers observed that severe side effects with placebo, long-acting lanreotide 90 mg and 120 mg were 0%, 7% and 16%, respectively.
Change in long-acting lanreotide after 6 months in these 3 groups included an increase of +36 mL, decrease of −82 mL, and decrease of -123 mL, respecitvely.
Based on ROC analysis, a reduction of 120 mL or more in liver volume has a positive predictive value of 64% for improving symptoms.
Dr Temmerman's team concludes, "Both long-acting lanreotide 90 mg and long-acting lanreotide120 mg reduce liver volume."
"Long-acting lanreotide 90 mg has less side effects. "
"This suggests that in case of intolerance to long-acting lanreotide 120 mg, a dose reduction to long-acting lanreotide 90 mg is meaningful."